 |
|
We continue from part
one in last month's issue.....
Right under their noses
On June 20, 1996, Diane Stem got a call at work. "It was my husband,
and all he said was, 'Di, you need to come home immediately.'
And I could tell from his tone that I didn't even want to ask
 why."
Diane's daughter, Stephanie, had come home earlier in the day,
gone upstairs and noticed that the heat seemed to be on.
She told her dad, who went to Ricky's room to see if he knew what
was happening. The door was locked, and Ricky didn't respond.
Ricky Sr. unlocked the door and found his son on his bedroom floor
with a plastic bag over his head.
"We had talked to Ricky about sex and about
drugs and about making good choices, but we never talked to him
about inhaling," Diane says. "We never did warn him." Like many
parents, she and her husband had never heard of huffing. "I don't
think he knew that it could kill him. He probably thought nobody
would ever know, and it wouldn't hurt anyone, and it wasn't illegal."
continue... The
local authorities
|
CANNIBINOID STUDY continued ----- Go to the top of this article
|
In three ways, 2-AG is hypothesized to help those who have suffered a brain injury: it decreases a toxic chemical, glutamate, reduces the amount of free radicals and TNF (a chemical that induces inflammation), all three released after injury, and lastly, the compound increases the blood supply to the brain. Because marijuana varies in its amount of THC, it is doubtful that the drug would be good treatment for head injuries.
With the assistance of the Hebrew University, Pharmos is scheduled commence the
|
final stage of clinical trials of Dexanabinol - a drug that has a host of similarities to THC. Because of the differences to THC, it does notbind to the same neural receptors.
As a result, it does not have the undesirable side effects. The drug appears, however, to cause a decrease in toxic chemicals and swelling. The first two phases of clinical trials were After the final phase of trials with the drug, the U.S. will initiate their own trials in early 2002.
|
|
M
E
D
I
C
A
L
|
